{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:03:24Z","timestamp":1792411404201,"version":"4.4.0"},"reference-count":85,"publisher":"International Society of Global Health","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Glob Health"],"DOI":"10.7189\/jogh.15.04250","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T11:18:04Z","timestamp":1756466284000},"source":"Crossref","is-referenced-by-count":2,"title":["BNT162b2 COVID-19 vaccination uptake, safety, effectiveness, and waning in children and young people aged 5\u201311 years in Scotland"],"prefix":"10.7189","volume":"15","author":[{"given":"Igor","family":"Rudan","sequence":"first","affiliation":[{"name":"Usher Institute, The University of Edinburgh, Edinburgh, UK"},{"name":"Nuffield Department of Primary Care Health Sciences, Oxford University, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kerr","sequence":"additional","affiliation":[{"name":"Usher Institute, The University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Public Health Scotland, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Jeffrey","sequence":"additional","affiliation":[{"name":"Public Health Scotland, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Grange","sequence":"additional","affiliation":[{"name":"Public Health Scotland, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Fenton","sequence":"additional","affiliation":[{"name":"Public Health Scotland, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanj","family":"Kurdi","sequence":"additional","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde University, Glasgow, UK"},{"name":"College of Pharmacy, Hawler Medical University, Erbil, Kurdistan Region, Iraq"},{"name":"College of Pharmacy, Al-Kitab University, Kirkuk, Iraq"},{"name":"Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Shi","sequence":"additional","affiliation":[{"name":"Usher Institute, The University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Cullen","sequence":"additional","affiliation":[{"name":"Public Health Scotland, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin R","family":"Simpson","sequence":"additional","affiliation":[{"name":"Usher Institute, The University of Edinburgh, Edinburgh, UK"},{"name":"School of Health, Wellington Faculty of Health, Victoria University of Wellington, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasa Vittal","family":"Katikireddi","sequence":"additional","affiliation":[{"name":"MRC\/CSO Social & Public Health Sciences Unit, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis D","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Academic Primary Care, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Robertson","sequence":"additional","affiliation":[{"name":"Public Health Scotland, Glasgow, UK"},{"name":"Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Sheikh","sequence":"additional","affiliation":[{"name":"Usher Institute, The University of Edinburgh, Edinburgh, UK"},{"name":"Nuffield Department of Primary Care Health Sciences, Oxford University, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4223","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"key-10.7189\/jogh.15.04250-202508281831-R1","doi-asserted-by":"publisher","first-page":"01010","DOI":"10.7189\/jogh.11.01010","article-title":"The COVID-19 pandemic in children and young people during 2020\u20132021: Learning about clinical presentation, patterns of spread, viral load, diagnosis and treatment.","volume":"11","author":"Rudan","year":"2021","journal-title":"J Glob Health"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R2","doi-asserted-by":"publisher","first-page":"01011","DOI":"10.7189\/jogh.11.01011","article-title":"The COVID-19 pandemic in children and young people during 2020\u20132021: A complex discussion on vaccination.","volume":"11","author":"Rudan","year":"2021","journal-title":"J Glob Health"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"C4591001 Clinical Trial Group. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.","volume":"385","author":"Frenck","year":"2021","journal-title":"N Engl J Med"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R4","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1056\/NEJMoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.","volume":"385","author":"Ali","year":"2021","journal-title":"N Engl J Med"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1473-3099(21)00462-X","article-title":"Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1\/2 trial.","volume":"22","author":"Xia","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R6","doi-asserted-by":"publisher","first-page":"e783","DOI":"10.1093\/cid\/ciab845","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial.","volume":"75","author":"Zhu","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"C4591007 Clinical Trial Group. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.","volume":"386","author":"Walter","year":"2022","journal-title":"N Engl J Med"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R8","doi-asserted-by":"publisher","first-page":"100513","DOI":"10.1016\/j.lanepe.2022.100513","article-title":"BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12\u201317 years in Scotland.","volume":"23","author":"Rudan","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R9","doi-asserted-by":"publisher","first-page":"03006","DOI":"10.7189\/jogh.14.03006","article-title":"Caveats in reporting of national vaccine uptake.","volume":"14","author":"Millington","year":"2024","journal-title":"J Glob Health"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R10","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/vaccines9101102","article-title":"Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review.","volume":"9","author":"Lv","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R11","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.15585\/mmwr.mm7035e1","article-title":"COVID-19 Vaccination Coverage Among Adolescents Aged 12\u201317 Years \u2013 United States, December 14, 2020-July 31, 2021.","volume":"70","author":"Murthy","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/apa.16157","article-title":"Vaccinating children and adolescents against severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), updated data from Israel.","volume":"111","author":"Glikman","year":"2022","journal-title":"Acta Paediatr"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R13","doi-asserted-by":"publisher","first-page":"e2021052478","DOI":"10.1542\/peds.2021-052478","article-title":"Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination.","volume":"148","author":"Marshall","year":"2021","journal-title":"Pediatrics"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R14","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1016\/j.vaccine.2021.05.087","article-title":"Myocarditis following COVID-19 mRNA vaccination.","volume":"39","author":"Abu Mouch","year":"2021","journal-title":"Vaccine"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R15","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel.","volume":"385","author":"Mevorach","year":"2021","journal-title":"N Engl J Med"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R16","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1001\/jama.2021.14237","article-title":"Adolescent Myocarditis After COVID-19 Vaccination Is Rare.","volume":"326","author":"Kuehn","year":"2021","journal-title":"JAMA"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R17","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.15585\/mmwr.mm7031e1","article-title":"COVID-19 Vaccine Safety in Adolescents Aged 12\u201317 Years \u2013 United States, December 14, 2020-July 16, 2021.","volume":"70","author":"Hause","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R18","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/22221751.2022.2050952","article-title":"Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study.","volume":"11","author":"Lai","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.vaccine.2021.12.044","article-title":"Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents.","volume":"40","author":"June Choe","year":"2022","journal-title":"Vaccine"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.15585\/mmwr.mm7109e2","article-title":"Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years \u2013 United States, December 9, 2021-February 20, 2022.","volume":"71","author":"Hause","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R21","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.15585\/mmwr.mm705152a1","article-title":"COVID-19 Vaccine Safety in Children Aged 5-11 Years \u2013 United States, November 3-December 19, 2021.","volume":"70","author":"Hause","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R22","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.3201\/eid2711.211886","article-title":"Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021.","volume":"27","author":"Glatman-Freedman","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R23","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.15585\/mmwr.mm7042e1","article-title":"Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12-18 Years \u2013 United States, June-September 2021.","volume":"70","author":"Olson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R24","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1056\/NEJMc2114290","article-title":"Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents.","volume":"385","author":"Reis","year":"2021","journal-title":"N Engl J Med"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R25","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.15585\/mmwr.mm705152a2","article-title":"Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years \u2013 Arizona, July-December 2021.","volume":"70","author":"Lutrick","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R26","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1056\/NEJMoa2117995","article-title":"Overcoming Covid-19 Investigators. Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents.","volume":"386","author":"Olson","year":"2022","journal-title":"N Engl J Med"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R27","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa2202826","article-title":"Overcoming Covid-19 Investigators. BNT162b2 Protection against the Omicron Variant in Children and Adolescents.","volume":"386","author":"Price","year":"2022","journal-title":"N Engl J Med"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R28","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jama.2023.27022","article-title":"Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.","volume":"331","author":"Feldstein","year":"2024","journal-title":"JAMA"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0140-6736(22)01185-0","article-title":"Italian National COVID-19 Integrated Surveillance System and the Italian COVID-19 vaccines registry. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.","volume":"400","author":"Sacco","year":"2022","journal-title":"Lancet"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1473-3099(22)00177-3","article-title":"Effectiveness of BNT162b2 against COVID-19 in adolescents.","volume":"22","author":"Powell","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.15585\/mmwr.mm7111e1","article-title":"Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years \u2013 PROTECT Cohort, July 2021-February 2022.","volume":"71","author":"Fowlkes","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R32","doi-asserted-by":"publisher","first-page":"352","DOI":"10.15585\/mmwr.mm7109e3","article-title":"Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years \u2013 VISION Network, 10 States, April 2021-January 2022.","volume":"71","author":"Klein","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R34","unstructured":"UK Health Security Agency. COVID-19 vaccination: resources for children and young people aged 12 to 17 years. gov.uk. 1 February 2022 Available: https:\/\/www.gov.uk\/government\/publications\/covid-19-vaccination-resources-for-children-and-young-people. Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R35","unstructured":"Joint Committee on Vaccination and Immunisation. gov.uk. 2025. Available: https:\/\/www.gov.uk\/government\/groups\/joint-committee-on-vaccination-and-immunisation. Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R36","unstructured":"NHS inform. Vaccinating children and young people aged 12 to 17 years. 1 July 2025. Available: https:\/\/www.nhsinform.scot\/covid19vaccine\/. Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R37","unstructured":"Vaccine Adverse Event Reporting System (VAERS). Available: https:\/\/vaers.hhs.gov\/. Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R38","doi-asserted-by":"publisher","first-page":"03037","DOI":"10.7189\/jogh.14.03037","article-title":"Selecting the most informative positive and negative controls for self-controlled case series (SCCS): Rationale, approach, and lessons from studies investigating the safety of COVID-19 vaccines.","volume":"14","author":"Rudan","year":"2024","journal-title":"J Glob Health"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R39","doi-asserted-by":"publisher","first-page":"04101","DOI":"10.7189\/jogh.13.04101","article-title":"Understanding and reporting odds ratios as rate-ratio estimates in case-control studies.","volume":"13","author":"Kerr","year":"2023","journal-title":"J Glob Health"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R40","unstructured":"Scottish Government. Vaccination for 16 to 17-year-olds. 4 August 2021. Available: https:\/\/www.gov.scot\/news\/vaccinations-for-16-to-17-year-olds\/. Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R41","unstructured":"Scottish Government. Vaccinations for 12 to 15-year-olds. 14 September 2021 Available: https:\/\/www.gov.scot\/news\/vaccinations-for-12-15-year-olds\/. Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R42","unstructured":"Scottish Government. Vaccinations for all 5 to 11-year-olds. 22 February 2022. Available: https:\/\/www.gov.scot\/news\/vaccinations-for-all-five-to-11-year-olds\/. Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R43","unstructured":"Public Health Scotland. Our areas of Work. 2022. Available: https:\/\/www.publichealthscotland.scot. Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R44","doi-asserted-by":"publisher","first-page":"05026","DOI":"10.7189\/jogh.11.05026","article-title":"Uptake, effectiveness and safety of COVID-19 vaccines in children and young people in Scotland: Protocol for early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II).","volume":"11","author":"Adeloye","year":"2021","journal-title":"J Glob Health"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R45","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/ije\/dyab028","article-title":"Cohort Profile: Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) Database.","volume":"50","author":"Mulholland","year":"2021","journal-title":"Int J Epidemiol"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R46","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","article-title":"Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.","volume":"397","author":"Sheikh","year":"2021","journal-title":"Lancet"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R47","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.","volume":"28","author":"Patone","year":"2022","journal-title":"Nat Med"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R48","unstructured":"Public Health Scotland. National respiratory infection and COVID-19 statistics. 6 March 2025. Available: https:\/\/publichealthscotland.scot\/our-areas-of-work\/covid-19\/covid-19-data-and-intelligence\/covid-19-weekly-report-for-scotland\/. Accessed: 31 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R49","unstructured":"World Health Organization. Module AESI. 30 July 2020. Available: https:\/\/www.who.int\/publications\/m\/item\/aesi-form-covid-19-vax Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R50","unstructured":"Brighton Collaboration. Safety Platform for Emergency vACcines (SPEAC). 13 November 2023. Available: https:\/\/brightoncollaboration.us\/speac\/. Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R51","doi-asserted-by":"crossref","unstructured":"Simpson CR, Lone N, Kavanagh K, Ritchie LD, Robertson C, Sheikh A, et al. Seasonal Influenza Vaccine Effectiveness (SIVE): an observational retrospective cohort study \u2013 exploitation of a unique community-based national-linked database to determine the effectiveness of the seasonal trivalent influenza vaccine. Southampton, UK: NIHR Journals Library; 2013. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK263263\/. Accessed: 26 March 2022.","DOI":"10.3310\/hsdr01100"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R52","unstructured":"International Classification of Diseases (ICD-10). Version: 2010. Available: https:\/\/icd.who.int\/browse10\/2010\/en. Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R53","unstructured":"Public Health Scotland. National Data Catalogue. 2025. Available: https:\/\/publichealthscotland.scot\/resources-and-tools\/health-intelligence-and-data-management\/national-data-catalogue\/. Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(21)02754-9","article-title":"Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.","volume":"399","author":"Katikireddi","year":"2022","journal-title":"Lancet"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R55","unstructured":"McCall B. Why Isn't the UK Vaccinating Young Children for COVID? Medscape; 17 December 2021. Available: https:\/\/www.medscape.com\/viewarticle\/965065. Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R56","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/MCP.0000000000000868","article-title":"COVID 19: vaccines, efficacy and effects on variants.","volume":"28","author":"Rudan","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R57","unstructured":"Imperial. Real-time Assessment of Community Transmission findings. 2022. Available: https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/react-study\/real-time-assessment-of-community-transmission-findings\/. Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R58","unstructured":"Gov.uk. Regulatory approval of Pfizer\/BioNTech vaccine for COVID-19. gov.uk. 2 December 2020. Available: https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19\/summary-of-product-characteristics-for-covid-19-vaccine-pfizerbiontech. Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R59","unstructured":"Office for National Statistics. Causes of Death. 2022. Available: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/causesofdeath\/ Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R60","unstructured":"Public Health Scotland. Data and intelligence. 2022. Available: https:\/\/www.isdscotland.org\/. Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R61","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1016\/S0140-6736(22)00791-7","article-title":"Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.","volume":"399","author":"Wong","year":"2022","journal-title":"Lancet"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R62","unstructured":"National Health Service. Paediatric Inflammatory Multisystem Syndrome (PIMS-Ts). November 2020. Available: https:\/\/www.gosh.nhs.uk\/conditions-and-treatments\/conditions-we-treat\/paediatric-inflammatory-multisystem-syndrome-pims\/. Accessed: 26 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R63","unstructured":"Weaver J. Using negative control outcomes to identify biased study design: A self-controlled case series example. 2022. Available: https:\/\/www.ohdsi.org\/wp-content\/uploads\/2015\/04\/FluAmiSccs.pdf. Accessed: 27 July 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R64","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R65","doi-asserted-by":"publisher","first-page":"n1931","DOI":"10.1136\/bmj.n1931","article-title":"Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.","volume":"374","author":"Hippisley-Cox","year":"2021","journal-title":"BMJ"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R66","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies.","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R67","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamapediatrics.2022.6243","article-title":"Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years: A Systematic Review and Meta-analysis.","volume":"177","author":"Watanabe","year":"2023","journal-title":"JAMA Pediatr"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R68","doi-asserted-by":"publisher","first-page":"1474045","DOI":"10.3389\/fmed.2024.1474045","article-title":"Biases in COVID-19 vaccine effectiveness studies using cohort design.","volume":"11","author":"Agampodi","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R69","doi-asserted-by":"publisher","first-page":"100075","DOI":"10.1016\/j.lanepe.2021.100075","article-title":"Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS): Prospective, national surveillance, United Kingdom and Ireland, 2020.","volume":"3","author":"Flood","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R70","unstructured":"Public Health Scotland. COVID-19 & Winter Statistical Report. Edinburgh, UK: Public Health Scotland; 2022. Available: https:\/\/publichealthscotland.scot\/media\/12575\/22-04-06-covid19-winter_publication_report.pdf. Accessed: 31 March 2022."},{"key":"key-10.7189\/jogh.15.04250-202508281831-R71","doi-asserted-by":"crossref","unstructured":"Florentino PTV, Millington T, Cerqueira-Silva T, Robertson C, de Ara\u00fajo OV, J\u00fanior JB, et al. Vaccine effectiveness of two-dose BNT162b2 over time against COVID-19 symptomatic infection and severe cases among adolescents: Test negative design case-control studies in Brazil and Scotland. SSRN [preprint]. 5 April 2022. Available: http:\/\/dx.doi.org\/10.2139\/ssrn.4074678. Accessed: 27 July 2022.","DOI":"10.2139\/ssrn.4074678"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R72","doi-asserted-by":"publisher","first-page":"e37821","DOI":"10.2196\/37821","article-title":"Methodological issues for using a common data model (CDM) of COVID-19 vaccine uptake and important adverse events of interest (AEIs): the Data and Connectivity COVID-19 Vaccines Pharmacovigilance (DaC-VaP) United Kingdom feasibility study.","volume":"6","author":"Delanerolle","year":"2022","journal-title":"JMIR Form Res"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R73","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","article-title":"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.","volume":"27","author":"Simpson","year":"2021","journal-title":"Nat Med"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R74","doi-asserted-by":"publisher","first-page":"e1003927","DOI":"10.1371\/journal.pmed.1003927","article-title":"First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.","volume":"19","author":"Kerr","year":"2022","journal-title":"PLoS Med"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R75","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/S0140-6736(21)00677-2","article-title":"Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.","volume":"397","author":"Vasileiou","year":"2021","journal-title":"Lancet"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R76","doi-asserted-by":"publisher","first-page":"05025","DOI":"10.7189\/jogh.12.05025","article-title":"COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland.","volume":"12","author":"Kerr","year":"2022","journal-title":"J Glob Health"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R77","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1473-3099(22)00141-4","article-title":"EAVE II Collaborators. Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design.","volume":"22","author":"Sheikh","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R78","doi-asserted-by":"publisher","first-page":"829176","DOI":"10.3389\/fpubh.2022.829176","article-title":"Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Adolescents, Children, and Infants: A Systematic Review and Meta-Analysis.","volume":"10","author":"Du","year":"2022","journal-title":"Front Public Health"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R79","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1001\/jama.2022.7493","article-title":"Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.","volume":"327","author":"Fleming-Dutra","year":"2022","journal-title":"JAMA"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R80","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1136\/archdischild-2021-321604","article-title":"Sharing a household with children and risk of COVID-19: a study of over 300,000 adults living in healthcare worker households in Scotland.","volume":"106","author":"Wood","year":"2021","journal-title":"Arch Dis Child"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R81","doi-asserted-by":"publisher","first-page":"n2060","DOI":"10.1136\/bmj.n2060","article-title":"Risk of hospital admission with covid-19 among teachers compared with healthcare workers and other adults of working age in Scotland, March 2020 to July 2021: population based case-control study.","volume":"374","author":"Fenton","year":"2021","journal-title":"BMJ"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R82","doi-asserted-by":"publisher","first-page":"767447","DOI":"10.3389\/fpubh.2021.767447","article-title":"Effect of a Concise Educational Program on COVID-19 Vaccination Attitudes.","volume":"9","author":"Kaim","year":"2021","journal-title":"Front Public Health"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R83","doi-asserted-by":"publisher","first-page":"100584","DOI":"10.1016\/j.hlpt.2021.100584","article-title":"Finding the way forward: COVID-19 vaccination progress in Germany, Austria and Switzerland.","volume":"11","author":"Desson","year":"2022","journal-title":"Health Policy Technol"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R84","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1016\/j.vaccine.2021.10.077","article-title":"Social inequalities in COVID-19 vaccine acceptance and uptake for children and adolescents in Montreal, Canada.","volume":"39","author":"McKinnon","year":"2021","journal-title":"Vaccine"},{"key":"key-10.7189\/jogh.15.04250-202508281831-R85","doi-asserted-by":"publisher","first-page":"997","DOI":"10.15585\/mmwr.mm7028e1","article-title":"Acceptability of Adolescent COVID-19 Vaccination Among Adolescents and Parents of Adolescents - United States, April 15-23, 2021.","volume":"70","author":"Scherer","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Journal of Global Health"],"original-title":[],"link":[{"URL":"https:\/\/jogh.org\/2025\/jogh-15-04250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T11:18:21Z","timestamp":1756466301000},"score":1,"resource":{"primary":{"URL":"https:\/\/jogh.org\/2025\/jogh-15-04250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":85,"URL":"https:\/\/doi.org\/10.7189\/jogh.15.04250","relation":{},"ISSN":["2047-2978","2047-2986"],"issn-type":[{"value":"2047-2978","type":"print"},{"value":"2047-2986","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"article-number":"04250"}}